EUDA Health Holdings Ltd director Huang Bo filed an initial statement of beneficial ownership as a new insider. This Form 3 filing does not report any share purchases, sales, or other transactions, and instead serves to formally register Huang Bo’s status as a reporting person for EUDA Health.
EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.
Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.
EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Limited reports a new agreement with its institutional investor around an existing convertible note. The investor originally agreed to purchase up to $10,000,000 in convertible promissory notes and had already bought a $1,000,000 note that converts into ordinary shares at an 85% discount each time it converts. The company now has delivered 41,620 ordinary shares at a conversion price of $0.901 per share and both parties have mutually waived past breaches of the note and related agreement. In return, the investor agreed not to make further conversions until December 15, 2025, unless EUDA’s Nasdaq closing price reaches $2.00 or higher for three consecutive trading days. EUDA also states it does not intend to purchase any additional notes under the note purchase agreement.
EUDA Health Holdings Limited filed an amended Form 20-F to replace only page F-1 of its original annual report for the year ended December 31, 2024. All other disclosures from the original filing remain unchanged.
The independent auditor issued an unqualified opinion on the 2024 consolidated financial statements, stating they present fairly the company’s financial position and results in conformity with U.S. GAAP. However, the auditor highlighted that EUDA has an accumulated deficit of $50,100,426 and a shareholders’ equity deficit of $2,553,059 as of December 31, 2024, which raises substantial doubt about its ability to continue as a going concern.
As of December 31, 2024, EUDA had 37,153,049 ordinary shares outstanding and is listed on the Nasdaq Stock Market.
EUDA Health Holdings Limited, a foreign private issuer based in Singapore, submitted a Form 6-K for September 2025. The company reports an “Other Events” item and furnished a press release dated September 10, 2025, as Exhibit 99.1.
The report is signed by Interim Chief Financial Officer Vivian Tay on behalf of the company.
EUDA Health Holdings Limited submitted a Form 6-K as a foreign private issuer to furnish a company press release as an exhibit. The report is categorized as an "Other Events" update and is tied to a press release dated September 4, 2025.
The filing is signed on behalf of the company by Interim Chief Financial Officer Vivian Tay, indicating management’s authorization of this disclosure under the Securities Exchange Act of 1934.